Logo

Biomatters' Geneious Biologics SAAS

Dec 12, 2017

Biomatters has released a new version of Geneious Biologics, an enterprise software-as-a-service solution for commercial antibody screening and discovery. The new release features a capability that will allow developers of biological drugs to analyze millions of raw antibody sequences in minutes, accelerating the identification of therapeutic antibody candidates. The software enables users to preview, annotate, and compare NGS sequnces with no manual intervention, the company noted.

Breaking News
The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.